001); and 156 patiente in the ramipril group had a stroke, as compared with 226 patients in the placebo group (relative risk, 0. "2(p1217) phase 4 often reveals new uses for drugs or higher incidences or new types of ades. "given the primary findings of the dream trial, ramipril cannot be recommended for the prevention of type 2 diabetes," they wrote. Analysis of the hope data also indicated that patients with cardiovascular disease treated with ramipril were 34% less likely to report a new diagnosis of diabetes compared to those randomized to placebo.